Li, Y., Chu, Y., Shi, G., Wang, X., Ye, W., Shan, C., . . . Wu, H. (2022). A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer. Acta Pharmaceutica Sinica B, 12(11), 4165. https://doi.org/10.1016/j.apsb.2022.05.003
Chicago Style (17th ed.) CitationLi, Yan, et al. "A Novel Inhibitor of ARfl and ARv7 Induces Protein Degradation to Overcome Enzalutamide Resistance in Advanced Prostate Cancer." Acta Pharmaceutica Sinica B 12, no. 11 (2022): 4165. https://doi.org/10.1016/j.apsb.2022.05.003.
MLA (9th ed.) CitationLi, Yan, et al. "A Novel Inhibitor of ARfl and ARv7 Induces Protein Degradation to Overcome Enzalutamide Resistance in Advanced Prostate Cancer." Acta Pharmaceutica Sinica B, vol. 12, no. 11, 2022, p. 4165, https://doi.org/10.1016/j.apsb.2022.05.003.